{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T10:32:58Z","timestamp":1750156378439,"version":"3.37.3"},"reference-count":17,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.vaccine.2024.07.032","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T21:01:21Z","timestamp":1720818081000},"page":"126131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4344-9567","authenticated-orcid":false,"given":"Wan-Ting","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Law","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huyen","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Sch\u00f6nborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-I","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Buttery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivien Mun Yee","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Greinacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.07.032_b0005","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.07.032_b0010","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.07.032_b0015","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia","volume":"384","author":"Cines","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.07.032_b0020","unstructured":"Brighton Collaboration. Interim case definition of thrombosis with thrombocytopenia syndrome (TTS). <https:\/\/brightoncollaboration.org\/thrombosis-with-thrombocytopenia-syndrome-interim\/> [accessed 28 December 2023]."},{"key":"10.1016\/j.vaccine.2024.07.032_b0025","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJMc2307721","article-title":"Adenovirus-associated thrombocytopenia, thrombosis, and VITT-like antibodies","volume":"389","author":"Warkentin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.07.032_b0030","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood.2023022136","article-title":"Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure","volume":"142","author":"Sch\u00f6nborn","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2024.07.032_b0035","unstructured":"Brighton Collaboration. Request for review: TTS-VITT draft Brighton case definition. <https:\/\/brightoncollaboration.org\/request-for-review-tts-vitt-draft-brighton-case-definition\/> [accessed 28 December 2023]."},{"key":"10.1016\/j.vaccine.2024.07.032_b0040","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1016\/j.vaccine.2007.02.063","article-title":"The development of standardized case definitions and guidelines for adverse events following immunization","volume":"25","author":"Kohl","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.032_b0045","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.jtha.2023.06.027","article-title":"Long-term outcome in vaccine-induced immune thrombocytopenia and thrombosis","volume":"21","author":"Sch\u00f6nborn","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vaccine.2024.07.032_b0050","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"issue":"245\u20139","key":"10.1016\/j.vaccine.2024.07.032_b0055","first-page":"e1","article-title":"Australian New Zealand approach to diagnosis and management of vaccine induced immune thrombosis and thrombocytopenia","volume":"215","author":"Chen","year":"2021","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2024.07.032_b0060","unstructured":"Taiwan Food and Drug Administration. Summary of Covid-19 vaccine safety surveillance: as of 30 September 2023 [Chinese]. <https:\/\/www.fda.gov.tw\/tc\/includes\/GetFile.ashx?id=f638331478640715627&type=2&cid=45553> [accessed 28 December 2023]."},{"key":"10.1016\/j.vaccine.2024.07.032_b0065","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.vaccine.2024.01.045","article-title":"Thrombosis thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia with thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"42","author":"Sch\u00f6nborn","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.032_b0070","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1016\/j.vaccine.2023.08.079","article-title":"Background rates of adverse events of special interest for COVID-19 vaccines: a multinational Global Vaccine Data Network (GVDN) analysis","volume":"41","author":"Phillips","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.032_b0075","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1016\/j.vaccine.2022.09.001","article-title":"Thrombosis and thromboembolism: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"40","author":"Gollamudi","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.032_b0080","unstructured":"SPEAC. <https:\/\/speacsafety.net\/> [accessed 28 December 2023]."},{"key":"10.1016\/j.vaccine.2024.07.032_b0085","doi-asserted-by":"crossref","first-page":"e221142","DOI":"10.3201\/eid2903.221142","article-title":"The 100 Days Mission \u2014 2022 global pandemic preparedness summit","volume":"29","author":"Gouglas","year":"2023","journal-title":"Emerg Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24007941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24007941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T18:58:04Z","timestamp":1726167484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24007941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":17,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0264410X24007941"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.07.032","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.07.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126131"}}